Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus

At this time, the prehospital treatment of the status epilepticus use some molecule ("FOSPHENYLOINE") with large contra-indications. In this case the physician is not able to know the past medical history of the patient, the biological examinations and so he can not decide which molecules he can use.

The levetiracetam is a knowledge medication in the epilepsy since more than twenty years. One of specificity of the levetiracetam is to be able to be used in all situations (no clinical or biological contre-indication). This molecule seems like to be very interesting to be used in prehospital system.

The goal of this study is to evaluate the association levetiracetam / clonazepam in first line in the prehospital treatment of the status epilepticus

Inclusion criteria

• Age ≥ 18 years
• Patient taken care by a prehospital medical team participating in the study
• Diagnosis of tonicoclonic generalized status epilepticus confirmed on the spot by a physician of the team.

Exclusion criteria

• Parent or the reliable person indicated by the patient present not giving its agreement for the inclusion
• Pregnancy clinically detectable or known for close relations at the time of the status epilepticus
• tonicoclonic generalized status epilepticus after anoxia post cardiac arrest
• Patient having already received another treatment for the same episode of status epilepticus
• Patient having already participated in the study during a previous episode of status epilepticus
• Patient in "latent" status epilepticus. Definition : patient in the coma having epileptic demonstrations (CLONISMS MYOCLONISMS) small or invalid, contrasting with permanent generalized electric seizures on the EEG
• Patient presenting certain diagnosis of pseudo name psychogenic seizure
• Patient whose neurological status requires an immediate surgery (traumatism)
• Patient having a hyper-responsiveness about the levetiracetam or about the other by-products of pyrrolidone or an one of the excipients
• Patient having a hyper-responsiveness about the clonazepam, about the benzodiazepins or about one of the other constituents of the product
• Patient under medical guardianship
• Not membership in a schema of medical assurance.